The world journal of men's health · 2019
Sperm and Seminal Plasma Proteomics: Molecular Changes Associated with Varicocele-Mediated Male Infertility.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Bo Ra, Kim Hyun Ju, Kim Yong Bae, Kim Hee Seung, Song Jae Yun, Kim Dae-Yeon, Kim Jae Hoon, Kim Yun Hwan
Аннотация
OBJECTIVE: To investigate perceptual and practical differences regarding radiotherapy (RT) for recurrent ovarian cancer (ROC) among gynecologic oncologists (GOs) and radiation oncologists (ROs) in Korea.
METHODS: An anonymous cross-sectional survey was conducted from June 5 to September 5, 2024, targeting experienced members of the Korean Gynecologic Oncology Group and Korean Radiation Oncology Group. A structured questionnaire with approximately 25 main items covered 4 domains: demographics, perceptions/attitudes, practice patterns, and clinical case scenarios.
RESULTS: This study included 116 oncologists (80 GOs and 36 ROs; 47.1% and 45.6% response rate, respectively). Demographic characteristics (age, clinical experience, and patient volume) differed between groups (p<0.05). Although 68.8% of GOs and 91.7% of ROs considered RT effective, their primary goals differed: GOs prioritized local control (78.8%) and palliation (15.0%), whereas ROs emphasized local control (66.7%) and consolidation (22.2%) (p=0.016). Platinum-sensitive ROC, specific ROC subtypes, localized abdominal recurrence, and the definitions of oligometastasis (p<0.05) varied between GOs and ROs. Among GOs, 68% had partial knowledge of stereotactic ablative radiotherapy (SABR), citing low side effects (65%) as an advantage and limited indications (81%) as a disadvantage. Among ROs, SABR doses and fractionation protocols were relatively consistent for lung, liver, and spine lesions, whereas approaches varied significantly for abdominal lesions (p=0.029).
CONCLUSION: Although most oncologists recognize RT as effective for ROC, substantial differences in perception and clinical practice exist between GOs and ROs, highlighting the need for enhanced multidisciplinary collaboration and stronger clinical evidence to establish standardized treatment strategies for ROC.
METHODS: An anonymous cross-sectional survey was conducted from June 5 to September 5, 2024, targeting experienced members of the Korean Gynecologic Oncology Group and Korean Radiation Oncology Group. A structured questionnaire with approximately 25 main items covered 4 domains: demographics, perceptions/attitudes, practice patterns, and clinical case scenarios.
RESULTS: This study included 116 oncologists (80 GOs and 36 ROs; 47.1% and 45.6% response rate, respectively). Demographic characteristics (age, clinical experience, and patient volume) differed between groups (p<0.05). Although 68.8% of GOs and 91.7% of ROs considered RT effective, their primary goals differed: GOs prioritized local control (78.8%) and palliation (15.0%), whereas ROs emphasized local control (66.7%) and consolidation (22.2%) (p=0.016). Platinum-sensitive ROC, specific ROC subtypes, localized abdominal recurrence, and the definitions of oligometastasis (p<0.05) varied between GOs and ROs. Among GOs, 68% had partial knowledge of stereotactic ablative radiotherapy (SABR), citing low side effects (65%) as an advantage and limited indications (81%) as a disadvantage. Among ROs, SABR doses and fractionation protocols were relatively consistent for lung, liver, and spine lesions, whereas approaches varied significantly for abdominal lesions (p=0.029).
CONCLUSION: Although most oncologists recognize RT as effective for ROC, substantial differences in perception and clinical practice exist between GOs and ROs, highlighting the need for enhanced multidisciplinary collaboration and stronger clinical evidence to establish standardized treatment strategies for ROC.